Double bottom in GILDWonderful double bottom pattern spotted in GILD. It hasn't broken out yet. This chart is for educational purposes only. Please consult your financial advisor before making any buy or sell decision.
Next report date
April 24
Report period
Q1 2025
EPS estimate
1.63 EUR
Revenue estimate
6.28 B EUR
0.38 EUR
463.67 M EUR
27.75 B EUR
1.24 B
About Gilead Sciences, Inc.
Sector
Industry
CEO
Daniel P. O'Day
Website
Headquarters
Foster City
Founded
1987
FIGI
BBG00J7BM5F4
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
−75%
−50%
−25%
0%
25%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−8.00 B
−4.00 B
0.00
4.00 B
8.00 B
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
0.00
2.00 B
4.00 B
6.00 B
8.00 B
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
0.00
2.00 B
4.00 B
6.00 B
8.00 B
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
0.00
7.00 B
14.00 B
21.00 B
28.00 B
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GILD5050849
Gilead Sciences, Inc. 2.8% 01-OCT-2050Yield to maturity
6.72%
Maturity date
Oct 1, 2050
US375558BS1
GILEAD SCIEN 20/40Yield to maturity
6.21%
Maturity date
Oct 1, 2040
US375558BK8
GILEAD SCIENCES 16/47Yield to maturity
6.02%
Maturity date
Mar 1, 2047
GILD4184058
Gilead Sciences, Inc. 4.5% 01-FEB-2045Yield to maturity
5.82%
Maturity date
Feb 1, 2045
GISE
GILEAD SCIENCES 2046Yield to maturity
5.79%
Maturity date
Mar 1, 2046
GILD4104362
Gilead Sciences, Inc. 4.8% 01-APR-2044Yield to maturity
5.74%
Maturity date
Apr 1, 2044
GILD5939386
Gilead Sciences, Inc. 5.6% 15-NOV-2064Yield to maturity
5.69%
Maturity date
Nov 15, 2064
GILD5648609
Gilead Sciences, Inc. 5.55% 15-OCT-2053Yield to maturity
5.54%
Maturity date
Oct 15, 2053
GILD5939385
Gilead Sciences, Inc. 5.5% 15-NOV-2054Yield to maturity
5.52%
Maturity date
Nov 15, 2054
GILD.GO
Gilead Sciences, Inc. 5.65% 01-DEC-2041Yield to maturity
5.43%
Maturity date
Dec 1, 2041
GISG
GILEAD SCIENCES 16/36Yield to maturity
5.37%
Maturity date
Sep 1, 2036
See all 1GILD bonds
Curated watchlists where 1GILD is featured.
Frequently Asked Questions
The current price of 1GILD is 104.18 EUR — it has increased by 0.56% in the past 24 hours. Watch GILEAD SCIENCES stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange GILEAD SCIENCES stocks are traded under the ticker 1GILD.
1GILD stock has risen by 5.16% compared to the previous week, the month change is a −3.95% fall, over the last year GILEAD SCIENCES has showed a 53.88% increase.
We've gathered analysts' opinions on GILEAD SCIENCES future price: according to them, 1GILD price has a max estimate of 130.39 EUR and a min estimate of 83.82 EUR. Watch 1GILD chart and read a more detailed GILEAD SCIENCES stock forecast: see what analysts think of GILEAD SCIENCES and suggest that you do with its stocks.
1GILD reached its all-time high on Mar 4, 2025 with the price of 111.00 EUR, and its all-time low was 46.18 EUR and was reached on Dec 30, 2020. View more price dynamics on 1GILD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1GILD stock is 0.60% volatile and has beta coefficient of 0.55. Track GILEAD SCIENCES stock price on the chart and check out the list of the most volatile stocks — is GILEAD SCIENCES there?
Today GILEAD SCIENCES has the market capitalization of 128.98 B, it has increased by 3.96% over the last week.
Yes, you can track GILEAD SCIENCES financials in yearly and quarterly reports right on TradingView.
GILEAD SCIENCES is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
1GILD earnings for the last quarter are 1.84 EUR per share, whereas the estimation was 1.68 EUR resulting in a 9.35% surprise. The estimated earnings for the next quarter are 1.63 EUR per share. See more details about GILEAD SCIENCES earnings.
GILEAD SCIENCES revenue for the last quarter amounts to 7.31 B EUR, despite the estimated figure of 6.91 B EUR. In the next quarter, revenue is expected to reach 6.27 B EUR.
1GILD net income for the last quarter is 1.72 B EUR, while the quarter before that showed 1.13 B EUR of net income which accounts for 53.05% change. Track more GILEAD SCIENCES financial stats to get the full picture.
Yes, 1GILD dividends are paid quarterly. The last dividend per share was 0.73 EUR. As of today, Dividend Yield (TTM)% is 2.75%. Tracking GILEAD SCIENCES dividends might help you take more informed decisions.
GILEAD SCIENCES dividend yield was 3.33% in 2024, and payout ratio reached 805.23%. The year before the numbers were 3.70% and 66.62% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 2, 2025, the company has 17.6 K employees. See our rating of the largest employees — is GILEAD SCIENCES on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GILEAD SCIENCES EBITDA is 12.97 B EUR, and current EBITDA margin is 46.74%. See more stats in GILEAD SCIENCES financial statements.
Like other stocks, 1GILD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GILEAD SCIENCES stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GILEAD SCIENCES technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GILEAD SCIENCES stock shows the buy signal. See more of GILEAD SCIENCES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.